Pancreatic Cancer Research

ResearcherWayne State UniversityActive in the last 2 years

Boris Pasche

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3750-7898; OpenAlex author ID A5042254050. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  3. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  4. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  5. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis Co-author DOI 10.1101/2023.12.18.572102↗
  6. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Co-author DOI 10.1016/j.canlet.2020.12.008↗
  7. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-cen… Last author DOI 10.1016/s1470-2045(17)30314-5↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sahar F. Bannoura · 5 shared papers, 2023–2026 · strength 0.88
  2. Md. Hafiz Uddin · 5 shared papers, 2023–2026 · strength 0.88
  3. Mohammed Najeeb Al Hallak · 5 shared papers, 2023–2026 · strength 0.88
  4. Husain Yar Khan · 5 shared papers, 2023–2026 · strength 0.88
  5. Amro Aboukameel · 5 shared papers, 2023–2026 · strength 0.88
  6. Asfar Sohail Azmi · 5 shared papers, 2023–2026 · strength 0.88
  7. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
  8. Ramzi M. Mohammad · 4 shared papers, 2024–2026 · strength 0.72
  9. Bassel F. El‐Rayes · 4 shared papers, 2024–2026 · strength 0.72
  10. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
  11. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
  12. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  13. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
  14. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  15. Philip A. Philip · 2 shared papers, 2024–2025 · strength 0.35
  16. Kay‐Uwe Wagner · 2 shared papers, 2023–2024 · strength 0.33
  17. Wei Zhang · 2 shared papers, 2017–2021 · strength 0.17
  18. Steve H. Kim · 1 shared paper, 2025 · strength 0.17
  19. Longhao Sun · 1 shared paper, 2021 · strength 0.12
  20. Liang Liu · 1 shared paper, 2021 · strength 0.12
  21. Huamin Wang · 1 shared paper, 2021 · strength 0.12
  22. Ya’an Kang · 1 shared paper, 2021 · strength 0.12
  23. Jason B. Fleming · 1 shared paper, 2021 · strength 0.12
  24. Clancy J. Clark · 1 shared paper, 2017 · strength 0.05
  25. Angela Tatiana Alistar · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.